Obtenga las últimas noticias sobre las acciones de Indaptus Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de INDP

Últimas noticias sobre

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

News

Press Releases

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Earnings

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Health Care

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Small Cap

Opinion

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Indaptus Therapeutics Announces Reverse Stock Split

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Indaptus Therapeutics Provides Clinical Update

AUTL

CATX

INDP

ONCY

TSX:ONC

Aditxt

Apollomics

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Bio Green Med Solution, Inc. - 6% Convertible Preferred Stock

Bio Green Med Solution

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

GRI Bio

GT Biopharma

Kala Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Medicus Pharma

Oragenics

Onconetix

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

Maxim Group

HC Wainwright & Co.

Screenshot 2025-05-27 at 5.38.59 PM

Biotech

Reiteration

Indaptus Therapeutics Q1 Update: Company Advances Decoy20 Immunotherapy To Fight Cancer, Maxim Group Analyst Reiterates Buy Rating

Screenshot 2025-04-21 at 5.37.26 PM

General

Bacteria: The Surprising Tool In The Fight Against Cancer – And How Indaptus Is Taking It Further

Screenshot 2025-03-17 at 5.34.34 PM

Aggressive Cancers In Young People Are On The Rise – Can The Immune System Fight Back Better? Indaptus Therapeutics Thinks So

Comments

Indaptus Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL